*VOLGA研究* 不适合/拒绝顺铂化疗 @tompowles1 @MichvdHeijden @myESMO #ESMO26 @oncodaily @OncoAlert
🔴 EV+Durva 每3周一次，⬆️ pCR、EFS、OS
🟠 ≈20% ❌ 膀胱切除术
🟢 ct-DNA清除与EFS相关
🔵 ⬆️ 三联 EV+Durva/T 的毒性，降低剂量是否会影响结局？
🟣 少一点可能就够了，多一点会不会太多？
54 浏览 · 2 赞 · 2 转发 · 0 回复
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDarolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t
https://esmocongress.esmo.org来源：Maite Bourlon · x.com